Abstract
Background Vaccination of people with HIV (PWH) on suppressive antiretroviral therapy (ART) represents a novel approach for evaluating candidate broadly neutralizing antibody (bnAb) immunogens for preventive and therapeutic HIV vaccines. Given pre-existing immunity in PWH, the safety of this approach requires careful assessment prior to broader application. Here, we report on the design and safety of the RENEW-SHCS study which evaluates the immunization of PWH with BG505 SOSIP.v4.1-GT1.1, an immunogen engineered to induce precursors of CD4 binding site (CD4bs)- and V2-apex targeting bnAbs.
Methods RENEW-SHCS is a phase I, open-label, non-randomized vaccination trial evaluating a single dose of the recombinant germline-targeting envelope trimer BG505 SOSIP.v4.1-GT1.1 (GT1.1), adjuvanted with 3M052-AF and Aluminum hydroxide (alum), in PWH on suppressive ART enrolled from the Swiss HIV Cohort Study. Participants were previously classified as bnAb or non-neutralizing antibody (nnAb) inducers, with a target enrollment of 15 per group, and were monitored for safety and immunogenicity for 24 weeks while continuing standard ART. Due to an out-of-specification stability measurement of adjuvant 3M052-AF the trial was paused after 23 immunizations and subjected to an unscheduled interim safety and reactogenicity assessment comprising protocol defined outcome measures (adverse events, clinical laboratory measurements and HIV-1 viral load).
Results Twenty-three participants (10 bnAb and 13 nnAb inducers, median age 59 years, 17 male / 6 female) were vaccinated between March and August 2025 before interruption of the trial. All participants completed follow-up with full protocol adherence. The interim-safety analysis confirmed that no vaccine-related serious adverse events occurred. Solicited local (96%) and systemic (83%) reactions were common, predominantly grade 1–2, transient, and self-limited. Transient laboratory changes occurred but mostly remained within the normal range, with no vaccine-related grade 3 abnormalities. We observed predominantly transient local and systemic reactions, which were similar or milder to the reactogenicity profile reported for immunization of adult people without HIV (PWOH) with GT1.1 adjuvanted with AS01b reported in the IAVI C101 trial. No viral rebound under ART occurred. One participant experienced two viral blips (>50 HIV-1 RNA copies/ml), one before and one 16 weeks after vaccination with subsequent re-suppression. All others maintained viral suppression (<50 copies/ml) throughout follow-up.
Conclusion RENEW-SHCS demonstrated a favorable safety and reactogenicity profile of single dose immunization with GT1.1 in PWH, comparable to that observed in PWOH. The findings of this phase I study support the feasibility of vaccinating ART-treated PWH in trials of preventive and therapeutic HIV vaccine strategies.
Trial registration SNCTP000006192 | BASEC2024-01623. ClinicalTrials.gov NCT07769983
Competing Interest Statement
R.W.S. is listed as inventor on patent US9738688B2 submitted by Cornell University that covers the design of BG505 SOSIP Env trimers. R.W.S. is an inventor on a patent US11344618B2 submitted by Academisch Medisch Centrum that covers the design of GT HIV Env trimers. The authors declare no other competing interests.
Clinical Trial
NCT07769983
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
RENEW-SHCS was evaluated by the responsible local ethics committees, the Kantonale Ethikkommission Zürich and the Kantonale Ethikkommission Bern. Ethical approval by both committees was given as documented in BASEC2024-01623 (information available at https://swissethics.ch/en/raps) It was also approved as clinical trial with an investigational medicine product (IMP) by Swissmedic (SNCTP000006192). The trial adheres to the guidelines formulated by the International Committee on Harmonization for Good Clinical Practice in clinical studies. The trial is overseen by a Protocol and Safety Review Team (PSRT) and an independent safety monitoring committee (SMC). A study pharmacist at Zueripharm AG, Schlieren, Switzerland is responsible for vaccine preparation and accountability. The collected study data are transferred to a web-based electronic data capture (EDC) system, REDCap, and are subject to external monitoring through the clinical trial center (CTC) at the University Hospital Zurich.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to correct an author name. The author previously listed as Penny W. Moore has been corrected to Penny L. Moore. No other changes have been made to the manuscript.
Data Availability
All original data generated in this study are included in the article and Supplementary Material. Further inquiries should be directed to the corresponding author.
Funder Information Declared
